DelveInsight’s “Pulmonary Arterial Hypertension Pipeline Insight, 2026” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscape. It covers the Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Arterial Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight’s comprehensive Pulmonary Arterial Hypertension Pipeline Report @ Pulmonary Arterial Hypertension Pipeline Insight- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=pgnw&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report
- DelveInsight’s Pulmonary Arterial Hypertension pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Pulmonary Arterial Hypertension treatment.
- The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
- Promising Pulmonary Arterial Hypertension Pipeline Therapies such as Sotatercept and LIQ861, among others.
- Among the companies developing PAH therapies, Liquidia Technologies has its drug candidate in the most advanced stage — Preregistration.
Stay informed about the cutting-edge advancements in Pulmonary Arterial Hypertension treatments @ Pulmonary Arterial Hypertension Clinical Trials Assessment
The Pulmonary Arterial Hypertension Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Pulmonary Arterial Hypertension Pipeline Report also highlights the unmet needs with respect to Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension Overview
Pulmonary arterial hypertension is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. Tests commonly performed to diagnose PAH and rule out other diseases include echocardiography, blood tests, pulmonary function tests, chest X-rays, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test,” which measures how far an individual can walk in that time period. Pulmonary Arterial Hypertension treatment includes prostaglandins, endothelin receptor antagonists, and phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies.
Explore More Insights on the Report @ Pulmonary Arterial Hypertension Treatment Market Size
Pulmonary Arterial Hypertension Emerging Drugs Profile
- Sotatercept: Acceleron Pharma
Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is currently in Phase III clinical trial for the treatment of PAH.
- LIQ861: Liquidia Technologies
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia has resubmitted a New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).
For More Information on the Report @ Pulmonary Arterial Hypertension Prevalence
Key Factors Driving the Growth of the Pulmonary Arterial Hypertension Pipeline
- Increasing Disease Burden and Unmet Medical Needs — The rising prevalence of Pulmonary Arterial Hypertension and the need for more effective long-term therapies are major factors driving pipeline growth. Increasing awareness and earlier diagnosis are also contributing to the demand for advanced treatment options.
- Advancements in Novel Therapeutic Approaches — The pipeline is expanding due to the development of innovative therapies, including prostacyclin pathway agents, endothelin receptor antagonists, soluble guanylate cyclase stimulators, and gene-based treatment approaches aimed at improving patient outcomes.
- Strong Industry Participation — Leading pharmaceutical and biotechnology companies are actively investing in the PAH pipeline, focusing on next-generation therapies and strategic collaborations to strengthen their research and development efforts.
- Growing Clinical Trial Activity — A significant number of candidates are being evaluated across Phase I, Phase II, and Phase III clinical trials, reflecting the increasing momentum in the PAH therapeutic landscape and the potential for new product launches in the coming years.
- Regulatory Support for Rare Diseases — Favorable regulatory pathways, including orphan drug designation and expedited approval programs, are encouraging companies to accelerate the development of novel PAH therapies.
- Increased Research and Development Investments — Continuous investments in cardiovascular research, along with advances in precision medicine and targeted therapies, are further supporting the growth of the Pulmonary Arterial Hypertension pipeline.
The Pulmonary Arterial Hypertension Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension, with aggregate therapies developed by each company.
- It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension treatment.
- Pulmonary Arterial Hypertension Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
- Pulmonary Arterial Hypertension Drugs under development, based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements, and financing details for future advancement of the Pulmonary Arterial Hypertension market.
Pulmonary Arterial Hypertension Companies
Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as:
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Discover the latest advancements in Pulmonary Arterial Hypertension treatment by visiting our website @ Pulmonary Arterial Hypertension Market Drivers and Barriers, and Future Perspectives
Scope of the Pulmonary Arterial Hypertension Pipeline Report
- Coverage — Global
- Pulmonary Arterial Hypertension Companies — Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
- Pulmonary Arterial Hypertension Pipeline Therapies — Sotatercept, LIQ861, and others.
- Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Preregistration
Read the full details of the Pulmonary Arterial Hypertension Pipeline on our website, @ Pulmonary Arterial Hypertension Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Pulmonary Arterial Hypertension: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- Early Stage Products (Phase I)
- Preclinical/Discovery Stage Products
- Inactive Products
- Pulmonary Arterial Hypertension Key Companies
- Pulmonary Arterial Hypertension Key Products
- Pulmonary Arterial Hypertension – Unmet Needs
- Pulmonary Arterial Hypertension – Market Drivers and Barriers
- Pulmonary Arterial Hypertension – Future Perspectives and Conclusion
- Pulmonary Arterial Hypertension Analyst Views
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Pulmonary Arterial Hypertension Pipeline Advances as 55+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
DelveInsight’s “Pulmonary Arterial Hypertension Pipeline Insight, 2026” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscape. It covers the Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Arterial Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight’s comprehensive Pulmonary Arterial Hypertension Pipeline Report @ Pulmonary Arterial Hypertension Pipeline Insight- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report
• DelveInsight’s Pulmonary Arterial Hypertension pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Pulmonary Arterial Hypertension treatment.
• The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
• Promising Pulmonary Arterial Hypertension Pipeline Therapies such as Sotatercept and LIQ861, among others.
• Among the companies developing PAH therapies, Liquidia Technologies has its drug candidate in the most advanced stage — Preregistration.
Stay informed about the cutting-edge advancements in Pulmonary Arterial Hypertension treatments @ Pulmonary Arterial Hypertension Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
The Pulmonary Arterial Hypertension Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Pulmonary Arterial Hypertension Pipeline Report also highlights the unmet needs with respect to Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension Overview
Pulmonary arterial hypertension is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. Tests commonly performed to diagnose PAH and rule out other diseases include echocardiography, blood tests, pulmonary function tests, chest X-rays, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test,” which measures how far an individual can walk in that time period. Pulmonary Arterial Hypertension treatment includes prostaglandins, endothelin receptor antagonists, and phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies.
Explore More Insights on the Report @ Pulmonary Arterial Hypertension Treatment Market Size- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Pulmonary Arterial Hypertension Emerging Drugs Profile
• Sotatercept: Acceleron Pharma
Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is currently in Phase III clinical trial for the treatment of PAH.
• LIQ861: Liquidia Technologies
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia has resubmitted a New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).
For More Information on the Report @ Pulmonary Arterial Hypertension Prevalence- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Key Factors Driving the Growth of the Pulmonary Arterial Hypertension Pipeline
• Increasing Disease Burden and Unmet Medical Needs — The rising prevalence of Pulmonary Arterial Hypertension and the need for more effective long-term therapies are major factors driving pipeline growth. Increasing awareness and earlier diagnosis are also contributing to the demand for advanced treatment options.
• Advancements in Novel Therapeutic Approaches — The pipeline is expanding due to the development of innovative therapies, including prostacyclin pathway agents, endothelin receptor antagonists, soluble guanylate cyclase stimulators, and gene-based treatment approaches aimed at improving patient outcomes.
• Strong Industry Participation — Leading pharmaceutical and biotechnology companies are actively investing in the PAH pipeline, focusing on next-generation therapies and strategic collaborations to strengthen their research and development efforts.
• Growing Clinical Trial Activity — A significant number of candidates are being evaluated across Phase I, Phase II, and Phase III clinical trials, reflecting the increasing momentum in the PAH therapeutic landscape and the potential for new product launches in the coming years.
• Regulatory Support for Rare Diseases — Favorable regulatory pathways, including orphan drug designation and expedited approval programs, are encouraging companies to accelerate the development of novel PAH therapies.
• Increased Research and Development Investments — Continuous investments in cardiovascular research, along with advances in precision medicine and targeted therapies, are further supporting the growth of the Pulmonary Arterial Hypertension pipeline.
The Pulmonary Arterial Hypertension Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension, with aggregate therapies developed by each company.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension treatment.
• Pulmonary Arterial Hypertension Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
• Pulmonary Arterial Hypertension Drugs under development, based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements, and financing details for future advancement of the Pulmonary Arterial Hypertension market.
Pulmonary Arterial Hypertension Companies
Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as:
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Discover the latest advancements in Pulmonary Arterial Hypertension treatment by visiting our website @ Pulmonary Arterial Hypertension Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Scope of the Pulmonary Arterial Hypertension Pipeline Report
• Coverage — Global
• Pulmonary Arterial Hypertension Companies — Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
• Pulmonary Arterial Hypertension Pipeline Therapies — Sotatercept, LIQ861, and others.
• Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Preregistration
Read the full details of the Pulmonary Arterial Hypertension Pipeline on our website, @ Pulmonary Arterial Hypertension Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Table of Contents
• Introduction
• Executive Summary
• Pulmonary Arterial Hypertension: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
• Late Stage Products (Phase III)
• Mid Stage Products (Phase II)
• Early Stage Products (Phase I)
• Preclinical/Discovery Stage Products
• Inactive Products
• Pulmonary Arterial Hypertension Key Companies
• Pulmonary Arterial Hypertension Key Products
• Pulmonary Arterial Hypertension – Unmet Needs
• Pulmonary Arterial Hypertension – Market Drivers and Barriers
• Pulmonary Arterial Hypertension – Future Perspectives and Conclusion
• Pulmonary Arterial Hypertension Analyst Views
• Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
